Ranbaxy Laboratories Limited is a pharmaceutical industry. The Company manufactures and markets Pharmaceuticals; value added generic and branded generics. The Company’s product basket encompasses a wide therapeutic mix covering a majority of the chronic and acute and lifestyle disease segments such as cardiovascular, central nervous system, respiratory, dermatology, orthopedics, nutririonals and urology segments. The Company's products are: Simvastatin, Amoxy+Clav Potas Coin, Amoxycillin, Ciprofloxacin, Isotretinon, Cephalexin, Ketorolac Tromethamine, Cefaclor, Clarithromycin and Cefuroxime Axetil. The company’s segment includes: pharmaceuticals, which comprises manufacture and trading of formulations, active pharmaceuticals ingredients (API) and intermediate, generics, drug discovery and consumer health care products; Other businesses comprise of rendering of financial services. In November 2008, Daiichi Sankyo completed the acquisition of 63.92% interest in the Company.